Suppr超能文献

通过动态反应评估方法重新定义血液系统恶性肿瘤的预后:慢性粒细胞白血病、霍奇金淋巴瘤、弥漫性大B细胞淋巴瘤和多发性骨髓瘤的经验教训

Re-defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma.

作者信息

Jain Arihant, Jain Ankur, Malhotra Pankaj

机构信息

Department of Internal Medicine (Clinical Hematology Division), Postgraduate Institute of Medical Education and Research, Chandigarh, 4th Floor, F Block, Nehru Hospital, Chandigarh, 160012 India.

Department of Hematology, Vardhaman Mahavir Medical College, Safdarjung Hospital, New Delhi, 110029 India.

出版信息

Indian J Hematol Blood Transfus. 2020 Jul;36(3):447-457. doi: 10.1007/s12288-019-01213-7. Epub 2019 Oct 22.

Abstract

Risk-stratification is an essential management tool in defining prognosis of haematological neoplasms, both from patient and physician perspective. We define a new prognostic term "Dynamic Response Assessment Method(s) (DRAM)" as "method(s) used for re-stratifying disease prognosis at fixed intervals during the treatment course". The risk stratification is done after a fixed duration of treatment or chemotherapy cycles using sensitive techniques. The information obtained then can be used for further therapeutic decisions and prognostication. Currently, there is enough evidence that response to treatment improves the prognostic value of baseline disease variables in the management of Chronic Myeloid Leukemia, Hodgkin lymphoma, Diffuse Large B cell Lymphoma, and Multiple Myeloma. Through this review, we discuss the current evidence based application of "DRAM" to guide therapeutic decisions in these malignancies. We also discuss how the results of "DRAM" can be incorporated for redefining prognosis and counselling the patients with these selected hematologic malignancies.

摘要

从患者和医生的角度来看,风险分层是定义血液系统肿瘤预后的重要管理工具。我们将一个新的预后术语“动态反应评估方法(DRAM)”定义为“在治疗过程中以固定间隔对疾病预后进行重新分层所使用的方法”。风险分层是在经过固定疗程的治疗或化疗周期后,使用敏感技术进行的。然后获得的信息可用于进一步的治疗决策和预后判断。目前,有充分的证据表明,在慢性髓性白血病、霍奇金淋巴瘤、弥漫性大B细胞淋巴瘤和多发性骨髓瘤的管理中,治疗反应可提高基线疾病变量的预后价值。通过本综述,我们讨论了“DRAM”基于当前证据的应用,以指导这些恶性肿瘤的治疗决策。我们还讨论了如何将“DRAM”的结果纳入重新定义预后,并为这些选定血液系统恶性肿瘤的患者提供咨询。

相似文献

本文引用的文献

5
How I treat the young patient with multiple myeloma.我如何治疗多发性骨髓瘤的年轻患者。
Blood. 2018 Sep 13;132(11):1114-1124. doi: 10.1182/blood-2017-05-693606. Epub 2018 Jul 2.
6
8
Treatment-free remission in CML: who, how, and why?CML 无治疗缓解:谁、如何以及为何?
Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):102-109. doi: 10.1182/asheducation-2017.1.102.
9
Minimal residual disease analysis in myeloma - when, why and where.骨髓瘤中的微小残留病分析——时机、原因及地点
Leuk Lymphoma. 2018 Aug;59(8):1772-1784. doi: 10.1080/10428194.2017.1386304. Epub 2017 Oct 11.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验